Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab biosimilar - EirGenix

Next Previous
Drug Profile

Pertuzumab biosimilar - EirGenix

Alternative Names: EG-1206A; Perjeta

Latest Information Update: 22 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EirGenix
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 10 Oct 2025 EirGenix withdrawn prior to enrollment a phase III trial for HER2-positive Hormone Receptor-negative Early Breast Cancer (Combination therapy, Neoadjuvant therapy) (IV, Infusion) (IV, Infusion), following scientific advice from the US FDA and EMA, EirGenix streamlined the clinical development of EG1206A (biosimilar to Perjeta) and concluded that continuing the study was unnecessary (NCT06884254)
  • 25 Mar 2025 EirGenix plans a phase III trial for HER2-positive Hormone Receptor-negative Early Breast Cancer (Combination therapy, Neoadjuvant therapy) (IV, Infusion), in May 2025 (NCT06884254)
  • 22 Nov 2023 EirGenix plans a phase III trial for HER2 positive Breast cancer in unknown location

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top